Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Other Operating Expenses (2016 - 2023)

Plus Therapeutics (PSTV) has disclosed Other Operating Expenses for 13 consecutive years, with -$2000.0 as the latest value for Q1 2023.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$2000.0 in Q1 2023 year-over-year; TTM through Dec 2023 was -$2000.0, a 99.96% increase, with the full-year FY2021 number at -$66000.0, changed N/A from a year prior.
  • Other Operating Expenses was -$2000.0 for Q1 2023 at Plus Therapeutics, up from -$5.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $886000.0 in Q2 2020 to a low of -$5.7 million in Q4 2022.
  • A 5-year average of -$601625.0 and a median of $46000.0 in 2019 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: crashed 751.06% in 2019, then skyrocketed 813.4% in 2020.
  • Plus Therapeutics' Other Operating Expenses stood at -$306000.0 in 2019, then soared by 389.54% to $886000.0 in 2020, then crashed by 102.03% to -$18000.0 in 2021, then tumbled by 31444.44% to -$5.7 million in 2022, then skyrocketed by 99.96% to -$2000.0 in 2023.
  • Per Business Quant, the three most recent readings for PSTV's Other Operating Expenses are -$2000.0 (Q1 2023), -$5.7 million (Q4 2022), and -$18000.0 (Q3 2021).